Table 4.
Multivariable analysis of clinicopathological factors associated with DFS
| Characteristic | Hazard ratio (95% CI) | P value |
|---|---|---|
| Age | 1.02 (1.00-1.03) | .021 |
| Gender | ||
| Female | Reference | |
| Male | 1.59 (1.10-2.32) | .014 |
| cT | ||
| 1 or 2 | 0.93 (0.41-2.15) | .9 |
| 3 | Reference | |
| 4 | 1.99 (1.22-3.24) | .006 |
| cN | ||
| Negative | Reference | |
| Positive | 1.07 (0.68-1.67) | .8 |
| Locoregional staging method | ||
| ERUS | Reference | |
| MRI | 1.26 (0.73-2.15) | .4 |
| Neoadjuvant treatment | ||
| ChemoRT | Reference | |
| TNT | 1.31 (0.88-1.95) | .2 |
| Response | ||
| Incomplete | Reference | |
| Completea | 0.20 (0.10-0.39) | <.001 |
N = 535, 132 events. P-values are based on the Wald test.
Pathological CR or sustained cCR for 2 years.
Abbreviations: ERUS, endorectal ultrasound; MRI, magnetic resonance imaging; CR, complete response; cCR, clinical complete response.